Comparative Pharmacology
Head-to-head clinical analysis: MENTAX TC versus NIZORAL ANTI DANDRUFF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MENTAX TC versus NIZORAL ANTI DANDRUFF.
MENTAX-TC vs NIZORAL ANTI-DANDRUFF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MENTAX-TC (butenafine hydrochloride) is a benzylamine antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and disruption of membrane integrity, resulting in fungal cell death.
Ketoconazole, an imidazole antifungal agent, inhibits fungal cytochrome P450 14α-demethylase (CYP51), preventing the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes. This disrupts membrane integrity and function.
Apply a thin layer to affected area once daily for 2-4 weeks.
Apply to wet hair, lather, and leave on for 3-5 minutes before rinsing. Use twice weekly for 4 weeks, then as needed to control dandruff.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 16-24 hours), allowing once-daily dosing.
Terminal elimination half-life is biphasic: initial 2 hours, terminal 8 hours (range 6-10 hours). After topical application, systemic absorption is minimal, resulting in an effective half-life of 72-96 hours in skin.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine, ~60% in feces as metabolites, <1% in bile as unchanged drug.
Primarily fecal (57%) via biliary excretion as unchanged drug and metabolites; renal excretion accounts for approximately 13% (2-4% unchanged).
Category C
Category C
Topical Antifungal
Topical Antifungal